



Supplementary Figure 2. Characteristics of each donor leukopak used in *in vivo* study.

(A) Flow cytometry plots of CD4:CD8 expression. The ratio of CD4:CD8 of live T cells for each donor type is unchanged after CAR T lentivirus transduction when manufactured by Prodigy as previously reported (3). The CD4:CD8 ratio of the matching CAR-T cells are shown in Fig. 4A and documented in Supplementary Table 1.

(B) CD62L expression on peripheral blood CD4⁺ T cells. CD4⁺ T cells were stained with monoclonal antibodies to CD62L. The frequency of CD62L_{low} CD4⁺ T cells was highest in leukopak 1 compared to other donor leukopaks. In non-small lung cancer patients, the frequency of CD62L_{low}CD4⁺ T cells has been correlated with long-term responders to anti-PD1 therapy in a recently published study (4).